AstraZeneca Will Establish Antibiotic Subsidiary With $40 Million

The big pharma – one of the few still investing in antibiotic research – will create a stand-alone subsidiary to focus exclusively on early-stage antibiotic development.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet